Abstract: Systemic administration of intact, bacterially derived minicells results in rapid accumulation of the minicells in the microenvironment of a brain tumor, in therapeutically significant concentrations, without requiring endothelial endocytosis/transcytosis across the blood brain barrier or any other mechanism by which, pursuant to conventional approaches, nanoparticles have entered into that microenvironment. Accordingly, a wide variety of brain tumors, both primary and metastatic, can be treated by administering systemically a therapeutically effective amount of a composition comprised of a plurality of such minicells, each minicell being a vehicle for an active agent against the tumor, such as a radionuclide, a functional nucleic acid or a plasmid encoding one, or a chemotherapeutic agent.

Abstract: An orodispersible solid pharmaceutical dosage unit of estetrol is disclosed. The solid dosage unit is easy to manufacture and suited for sublingual, buccal or sublabial administration. The orodispersible solid pharmaceutical dosage unit can include at least 100 ?g of an estetrol component and pharmaceutically acceptable excipients. Methods of manufacturing the orodispersible solid pharmaceutical dosage unit are also disclosed.

Abstract: The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition.

Abstract: The present invention relates to an in-vivo bulking agent which can be used as a medicinal agent for prevention or treatment of at least one disease selected from the group consisting of urinary incontinence, fecal incontinence, and gastroesophageal reflux or as a filler for use in a plastic surgery procedure, and to a preparation method therefor. The in-vivo bulking agent can exhibit a bulking effect when injected into the body and particularly, is highly biocompatible because a first composition in which silicone particles are coated with a zwitterionic polymer having a surfactant property is introduced into a second composition, whereby the bulking agent can inhibit inflammatory reactions in vivo.

Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.

Abstract: At least one embodiment, relates to a method for making cosmetic emulsions comprising the steps of preparing a uniform (suspension) dispersion of at least one water soluble polymer in a mixture containing at least one fatty alcohol. The mixture is to be sufficiently uniform to be processed by flaking, pastillating, prilling or otherwise solidifying the mixture which is then to be added to a cosmetic emulsion oil phase before combining with a water phase.

Abstract: The present invention relates to low temperature process for preparing nanoparticles of porous crystalline Fe-, Al- or Ti-based MOF carboxylate materials with low polydispersity index, and uses thereof, particularly as catalyst support for carrying out heterogeneously catalyzed chemical reactions, or as gas storage/separation/purification material, or as matrix for encapsulating active principles (medicine, cosmetics).

Abstract: A graft polymer is provided, which includes a polymer backbone with a plurality of hydroxy groups, protection group modified histidine grafted onto the side of the polymer backbone, and hydrophilic polymer having terminal reactive group grafted onto the side of the polymer backbone. The graft polymer coating can be applied to metal material to form a composite material, which can be implanted into an organism to reduce adhesion problems.

Abstract: The present invention is a cannabidiol oral dosage form including predominantly or exclusively hemp pomace, compounded as a tablet or formulated within a capsule without the addition of synthetic excipients, fillers or other additives, not including the inevitable presence of some moisture and the optional presence of fungal or bacterial probiotics introduced prior to or during dosage form manufacturing, and with or without fermentation of the hemp pomace prior to the dosage form manufacturing process. The dosage forms contain dietary fiber, important to activity as the desired delivery system, having a ratio of one part soluble dietary fiber to 30 parts insoluble dietary fiber and delivers desirable/non hallucinogenic cannabinoids (CBD, CBG) in a ratio of 30:1 up to 120:1 to hallucinogenic cannabinoids (THC).

Abstract: Provided is a production method for a gel composition including steps (1) to (3) mentioned below: step (1) of mixing at room temperature a partial degradation product of the galactose moiety of galactoxyloglucan and an aqueous solvent to obtain a mixture; step (2) of cooling or freezing the mixture obtained in step (1); and step (3) of gelling the mixture cooled or frozen in step (2) by heating to obtain a gel composition that includes the galactose-partial degradation product.

Abstract: Borylated Amino Acid (“BAA”) compositions and methods of making BAAs are disclosed herein. Consequently, the BAAs can be administered to patients as a Neutron Capture Agent and provide a method of treating cancer, immunological disorders and other disease by utilizing a Neutron Capture Therapy modality.

Abstract: A once-a-day controlled release oral dosage form of methazolamide is provided. The dosage form comprises a therapeutically effective amount of methazolamide and a high molecular weight binder. The dosage is configured for once-daily administration to a subject in need thereof, and releases methazolamide over a period of about twenty-four hours.

Abstract: The invention relates to a process for producing food ingredients from Stevia rebaudiana plant and their use in food products, beverages and other consumables. Obtained compositions are useful as flavors, sweeteners, antioxidants, and other functional ingredients.

Abstract: The present invention provides a process for preparation of highly purified mogrosides mixture from low purity mogrosides mixture.

Abstract: The present invention provides liquid oral dosage form of lipid lowering agent suitable for oral administration to human or animals.

Abstract: Disclosed are topical composition for delivery of an active agent to keratinous tissue, comprising a low molecular weight chitosan that is covalently modified chitosan with octane sulfonic acid which are attached to the chitosan via sulfonamide linkages (OsC), an effective amount of an active agent, and a carrier, and wherein the chitosan has a molecular weight of about 50 kD to about 150 kD. Also disclosed are methods of making the compositions and methods of using the compositions that entail topical application.

Abstract: The present invention relates to compositions providing improved preservative efficacy. The present invention further relates to polyquaternium compound containing compositions having improved the antifungal activity. In certain embodiments, the present invention relates to ophthalmic compositions comprising a polyquaternium compound, a polyol or combination of polyols, borate compound, and an antimicrobial mixture comprising electrolytes and nutrients.

Abstract: The present invention concerns a method for producing a hydrogel comprising the following steps in succession: a first step (i) of providing at least one powder of an anionic polymer (A) and at least one chitosan powder (B) comprising amine functions (—NH2); a second step (ii) consisting in dry mixing at least the powders (A) and (B) from the first step in order to form a mixture of powders; a third step (iii) of suspending the mixture of powders obtained from the second step in an aqueous medium having a pH that can enable the anionic polymer (A) to be dissolved without dissolving the chitosan (B); a fourth step (iv) of adding an acid to the suspension obtained from the third step in order to form the hydrogel; or the third (iii) and fourth (iv) steps are replaced by a mixing fifth step (v), comprising mixing an acidified aqueous medium including at least one compound (C) comprising at least one unit of a hexose or a unit derived from a hexose, and/or at least one phosphate of said compound (C), with said

Abstract: The present invention relates to low temperature process for preparing nanoparticles of porous crystalline Fe-, Al- or Ti-based MOF carboxylate materials with low polydispersity index, and uses thereof, particularly as catalyst support for carrying out heterogeneously catalyzed chemical reactions, or as gas storage/separation/purification material, or as matrix for encapsulating active principles (medicine, cosmetics).

Abstract: The present invention relates to a composition that can be used as or as part of a wound dressing and to wound dressings comprising the same. More specifically, the present invention relates to a composition that disrupts and kills bacteria within a biofilm and also prevents biofilm formation. The composition comprises a first component selected from the group consisting of chitosan, chitin, derivatives of chitosan, derivatives of chitin, and combinations thereof; at least one triprotic acid and at least one solubilising acid.

Abstract: A method of treating a subject for smoking cessation including periodically administering to the subject a pharmaceutically effective amount of cefdinir to treat the subject. Cefdinir for use in treating a subject for smoking cessation. A pharmaceutical composition including a pharmaceutically effective amount of cefdinir for use in treating a subject for smoking cessation.

Abstract: The present disclosure provides sweetener compositions, methods of using these compositions, and foods, beverages, and syrups comprising these compositions. The sweetener composition can comprise a sweetener and a sweetness enhancer. The composition can further comprise at least one supplemental sweetness enhancer and/or a salt.

Abstract: The present invention relates to nanoparticles for encapsulating compounds, the preparation and uses thereof, comprising a casein matrix, a basic amino acid and a metal selected from a divalent metal, a trivalent metal and combinations thereof. Said nanoparticles can encapsulate a water soluble or fat soluble biologically active compound. The invention is applicable in the food, pharmaceutical and cosmetic sectors and in the nanotechnology sector.

Abstract: Provided herein are pharmaceutical compositions and kits useful for sensitizing a microorganism or a population of microorganisms to a quinolone antibiotic. In a particular aspect, a carbon source and an electron acceptor can sensitize an antibiotic persistent microorganism to treatment with a fluoroquinolone antibiotic. Methods for sensitizing a microorganism to a quinolone antibiotic, reducing the density-dependent persistence (DDP) of an antibiotic resistant microorganism, and reducing the number of persistent cells in a population are also provided. Theses compositions and methods are useful in treating infections resulting from high-density bacterial cultures, such as pneumonia, genitourinary infections, biofilms, prosthetic graft infections, sepsis, and endovascular infections.

Abstract: A method of preventing intramammary infection and accelerating involution by administration of a biological response modifier, specifically a chitosan solution, to the teat of a lactating mammal at drying-off A chitosan solution neutralized with a weak base such as ?-glycerophosphate can remain liquid at room temperature for injection into a teat, but can form a hydrogel at body temperature inside the teat. The neutralized chitosan solution can also be optionally co-administered with a teat sealant.

Abstract: What claimed is a method of sweetening or enhancing sweetening effect of a composition that is administered orally to an individual by adding a specific triterpene glycoside obtained from Momordica grosvenorii (Siraitia grosvenori).

Abstract: Provided are a photodegradable hydrogel in which cells can be embedded in the photodegradable gel without causing cytotoxicity when the cells are embedded in the photodegradable gel by allowing the cells to coexist at the time of preparation of the photodegradable gel, and which contains a protein as one of the main components; a culture device using the same; a method for forming tissue; and a method for separating cells. A photodegradable hydrogel is obtained by condensation of an alkyne group contained in a cyclooctyne ring or an azacyclooctyne ring of the following compound A with an azido group of the following compound B.

Abstract: Natural blue colorant compositions and methods of use thereof are provided. The colorant compositions include at least one acylated anthocyanin, such as a diacylated anthocyanin. The colorant composition can further include a buffer solution having a pH from about 6.0 to about 8.0 and a metal ion or salt form thereof. The colorant compositions can be derived from a natural product and provide a stable, blue colorant that can be used in food products.

Abstract: A computer-implemented method executed by a robotic system for performing a positional search process in an assembly task is presented. The method includes decomposing, by the robotic system, a perturbation motion into a plurality of actions, the perturbation motion being a motion for an assembly position searched by the robotic system, each action of the plurality of actions related to a specific direction. The method further includes performing reinforcement learning by selecting an action among decomposed actions and assembly movement actions at each step of the positional search process based on corresponding force-torque data received from at least one sensor associated with the robotic system. The method also includes outputting a best action at each step for completion of the assembly task as a result of the reinforcement learning.

Abstract: The invention relates to the field of metal-organic framework materials and the field of medical technology, relates to a method for inhibiting tumor angiogenesis or preventing and/or treating tumor, comprising administering to a subject in need thereof an effective amount of a metal-organic framework comprising Fe and ligand. The invention further relates to a method for inhibiting the expression of matrix metalloproteinase in a cell, comprising administering to the cell an effective amount of a metal-organic framework comprising Fe and ligand.

Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.

Abstract: A melt spun tobacco composition, e.g., in flake or particle form, for oral use in a mammal made by melt spinning comprising tobacco and/or a tobacco extract and at least one material which is solid at room temperature, which melts at or below 500° F., and carries from 1% to 70% of tobacco when processed through melt spinning, and solidifies again in less than 5 seconds after melt spinning.

Abstract: The present invention relates to a composition that can be used as or as part of a wound dressing and to wound dressings comprising the same. More specifically, the present invention relates to a composition that disrupts and kills bacteria within a biofilm and also prevents biofilm formation. The composition comprises a first component selected from the group consisting of chitosan, chitin, derivatives of chitosan, derivatives of chitin, and combinations thereof; at least one triprotic acid and at least one solubilising acid.

Abstract: The present invention relates to a composition having improved or enhanced fidelity and/or longevity of the fragrance profile, comprising fragrance materials in a diamond construction and at least one substantially non-odorous fragrance modulator. The invention also relates to methods of use of the compositions for perfuming suitable substrates, including hard surfaces and body parts, particularly skin and hair.

Abstract: An assay and a method for identifying a prebiotic to treat a subject in need thereof to promote intestinal barrier integrity or to blunt an inflammatory response are provided.

Abstract: Urea gellants that are suitable for use in liquid compositions. Liquid compositions that include urea gellants. Related processes.

Abstract: Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.

Abstract: A poly-[1-4]-D-glucosamine derivative comprising [1-4]-D-glucosamine recurring units and comprising a fluoropolyether chain bound to the nitrogen atom in the C-2 position of at least one of the [1-4]-D-glucosamine recurring units.

Abstract: A protein comprising a polypeptide sequence having at least 70% sequence identity to SEQ ID NO:6, SEQ ID NO:2 or SEQ ID NO:4. The protein has ketose 3-epimerase activity.

Abstract: Improved formulations containing substituted imidazole derivatives of the general formula 1, formula (I) wherein Y is —CH2— or —CO—, R1 is H, halo or hydroxy, R2 is H or halo, and R3 is H or lower alkyl (e.g. C1 to C4 alkyl, preferably C1 or C2 alkyl), or a pharmaceutically acceptable salt, such as an acid addition salt, e.g. the hydrochloride, of a compound of the general formula (I), are in solid fast-dispersing dosage form suitable for pre-gastric absorption.

Abstract: The presently disclosed subject matter concerns a microbial biopolymer comprising fucose in its composition. This biopolymer consists of a polysaccharide comprising fucose, which represents at least 10% of its composition. This fucose-containing polysaccharide also contains non-sugar components, namely, acyl group substituents. This disclosed subject matter also concerns the process for the production of the biopolymer, which is obtained cultivation of the bacterium Enterobacter A47 (DSM 23139), using glycerol or glycerol-rich mixtures as carbon sources. The fucose-containing biopolymer of the presently disclosed subject matter may be used in several industrial applications (e.g. pharmaceutical, cosmetics and agro-food industries) and in the treatment of industrial wastes (e.g. oil and metal recovery).

Abstract: Disclosed herein are sweetener compositions comprising at least one sweetener and at least one sweetness enhancer chosen from terpenes (such as sesquiterpenes, diterpenes, and triterpenes), flavonoids, amino acids, proteins, polyols, other known natural sweeteners (such as cinnamaldehydes, selligueians, hematoxylins), secodammarane glycosides, and analogues thereof, wherein the at least one sweetness enhancer is present in the composition in an amount at or below the sweetness detection threshold level of the sweetness ehancer, and the at least one sweetener and the at least one sweetness enhancer are different.

Abstract: The invention relates to a process for producing highly soluble compositions containing purified steviol glycosides from Stevia rebaudiana Bertoni plant extract, more particularly Rebaudioside D. Obtained highly soluble compositions are useful as non-caloric sweeteners or in combination with sugar or high intensity sweeteners in edible and chewable compositions such as beverages, confectionaries, bakery products, chewing gums and the like.

Abstract: A compound comprising: (a) a drug carrier comprising coumarin-labeled-cysteine tethered mesoporous silica nanoparticles (MSNs) loaded with a pharmaceutically active agent, and (b) a fluorescein isothiocyanate-?-cyclodextrin (FITC-?-CD) covalently linked to said cysteine and blocking the release of said pharmaceutically active agent from said nanoparticles, wherein cleavage of said covalent linkage removes said cyclodextrin and releases said pharmaceutically active agent, and said coumarin and said fluorescin form a donor-acceptor pair so that said drug carrier has a first emission wavelength when the covalent linkage is intact and the cyclodextrin said present and a second emission wavelength after cleavage of said covalent linkage to remove said cyclodextrin and release said pharmaceutically active agent.

Abstract: The present invention relates to a method for functionalizing a solid material surface with self assembling or self aggregating cyclodextrins, said method comprising the steps of: providing an adsorption solution comprising at least one modified cyclodextrins and at least one solvent; and contacting a solid material surface with the adsorption solution.

Abstract: An object of the present invention is to obtain a dispersion in which a water-repellent inorganic powder is dispersed in water. The dispersion can be handled easily because the dispersion medium is water. In the case of using the dispersion for cosmetics, the dispersion can be suitably used when an inorganic powder subjected to a water-repellent treatment is mixed in an aqueous cosmetic. A dispersion in which an inorganic powder subjected to a water-repellent organic surface treatment is uniformly dispersed in water, wherein the contents of a water-repellent inorganic powder, a dispersant, and water is 80% by weight or more based on the total amount of the dispersion.

Abstract: The present invention provides a hyaluronic acid derivative comprising disaccharide units of Formula (I), and a hyaluronic acid derivative/drug conjugate wherein one or more drugs are conjugated to the hyaluronic acid derivative.

Abstract: A pharmaceutical suspension formulation comprising a dose greater than 100 mg/5 ml Cefixime and pharmaceutically acceptable excipients.

Abstract: A pharmaceutical suspension dosage form comprising greater than 80 mg/ml and not more than 150 mg/ml of Cefixime and pharmaceutically acceptable excipients.

Abstract: A crystallized maltitol powder including a maltitol content greater than 99.5% by weight, characterized by a particle-size distribution by volume, determined by laser granulometry, having less than 20% particles less than 200 ?m in size, less than 6% particles less than 100 ?m in size, less than 2% particles less than 40 ?m in size and a pour value less than or equal to 10 seconds, an aerated density greater than 0.85 g/ml, a compacted density greater than 0.97 g/ml, and a compressibility of less than 17%, and to its use in the pharmaceuticals and above all foods sectors, in particular in the formulation of chocolates or table sweeteners.